The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.
Autoimmune Diseases Induced by TNF-Targeted Therapies: Analysis of 233 Cases
Abstract
Tumor necrosis factor (TNF)-targeted therapies are increasingly used for a rapidly expanding number of rheumatic and autoimmune diseases. With this use and longer follow-up periods of treatment, there are a growing number of reports of the development of autoimmune processes related to anti-TNF agents. We have analyzed the clinical characteristics, outcomes, and patterns of association with the different anti-TNF agents used in all reports of autoimmune diseases developing after TNF-targeted therapy found through a MEDLINE search of articles published between January 1990 and December 2006. We identified 233 cases of autoimmune diseases (vasculitis in 113, lupus in 92, interstitial lung diseases in 24, and other diseases in 4) secondary to TNF-targeted therapies in 226 patients. The anti-TNF agents were administered for rheumatoid arthritis (RA) in 187 (83%) patients, Crohn disease in 17, ankylosing spondylitis in 7, psoriatic arthritis in 6, juvenile RA in 5, and other diseases in 3. The anti-TNF agents administered were infliximab in 105 patients, etanercept in 96, adalimumab in 21, and other anti-TNF agents in 3. We found 92 reported cases of lupus following anti-TNF therapy (infliximab in 40 cases, etanercept in 37, and adalimumab in 15). Nearly half the cases fulfilled 4 or more classification criteria for systemic lupus erythematosus (SLE), which fell to one-third after discarding preexisting lupus-like features. One hundred thirteen patients developed vasculitis after receiving anti-TNF agents (etanercept in 59 cases, infliximab in 47, adalimumab in 5, and other agents in 2). Leukocytoclastic vasculitis was the most frequent type of vasculitis, and purpura was the most frequent cutaneous lesion. A significant finding was that one-quarter of patients with vasculitis related to anti-TNF agents had extracutaneous involvement. Twenty-four cases of interstitial lung disease associated with the use of anti-TNF agents were reported. In these patients, 2 specific characteristics should be highlighted: the poor prognosis in spite of cessation of anti-TNF therapy, and the possible adjuvant role of concomitant methotrexate. In conclusion, the use of anti-TNF agents has been associated with an increasing number of cases of autoimmune diseases, principally cutaneous vasculitis, lupus-like syndrome, SLE, and interstitial lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hochberg, M. C. (1997) · Arthritis & Rheumatism · doi:10.1002/art.1780400928 · Cited by 11,409
Nomenclature of Systemic Vasculitides
Jennette, J. C., Falk, R. J., Andrassy, K., Bacon, P. A., Churg, J., Gross, W. L., Hagen, E. C., Hoffman, G. S., Hunder, G. G., Kallenberg, C. G. M., et al. (1994) · Arthritis & Rheumatism · doi:10.1002/art.1780370206 · Cited by 3,845
Bongartz, T., Sutton, A. J., Sweeting, M. J., Buchan, I., Matteson, E. L., & Montori, V. (2006) · JAMA · doi:10.1001/jama.295.19.2275 · Cited by 2,468
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
Wolfe, F., & Michaud, K. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20311 · Cited by 644
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Furst, D., Weisman, M. H., St.Clair, E. W., Keenan, G. F., van der Heijde, D., Marsters, P. A., et al. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20159 · Cited by 514
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Shakoor, N., Michalska, M., Harris, C. A., & Block, J. A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07714-0 · Cited by 458
De Bandt, M., Sibilia, J., Le Loët, X., Prouzeau, S., Fautrel, B., Marcelli, C., Boucquillard, E., Siame, J. L., Mariette, X., & Inflammation, T. C. R. E. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1715 · Cited by 401
Schiff, M. H., Burmester, G. R., Kent, J. D., Pangan, A. L., Kupper, H., Fitzpatrick, S. B., & Donovan, C. (2006) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.043166 · Cited by 390
Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy
Kroesen, S. (2003) · Rheumatology · doi:10.1093/rheumatology/keg263 · Cited by 328
Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis
Stokes, M. B., Foster, K., Markowitz, G. S., Ebrahimi, F., Hines, W., Kaufman, D., Moore, B., Wolde, D., & D'Agati, V. D. (2005) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh832 · Cited by 266
Flendrie, M., Vissers, W. H., Creemers, M. C., de Jong, E. M., van de Kerkhof, P. C., & van Riel, P. L. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1724 · Cited by 259
Rubin, R. L. (2005) · Toxicology · doi:10.1016/j.tox.2004.12.025 · Cited by 239
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα
Eriksson, C., Engstrand, S., Sundqvist, K.-G., & Rantapää-Dahlqvist, S. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2004.024182 · Cited by 228
Vasculitis in Systemic Lupus Erythematosus: Prevalence and Clinical Characteristics in 670 Patients
Ramos-Casals, M., Nardi, N., Lagrutta, M., Brito-Zerón, P., Bové, A., Delgado, G., Cervera, R., Ingelmo, M., & Font, J. (2006) · Medicine · doi:10.1097/01.md.0000216817.35937.70 · Cited by 217
Self-citationLeukocytoclastic vasculitis associated with tumor necrosis factor-alpha blocking agents.
Mohan, N., Edwards, E. T., Cupps, T. R., Slifman, N. R., Jong-Hoon, L., Siegel, J. N., & Braun, M. M. (2004) · PubMed · Cited by 200
Vasculitides induced by TNFα antagonists: a study in 39 patients in France
Marcoux, B. S., & Bandt, M. D. (2006) · Joint Bone Spine · doi:10.1016/j.jbspin.2006.02.010 · Cited by 190
Font, J. (2004) · Seminars in Arthritis and Rheumatism · doi:10.1053/s0049-0172(03)00133-1 · Cited by 182
Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series.
Jarrett, S. J., Cunnane, G., Conaghan, P. G., Bingham, S. J., Buch, M. H., Quinn, M. A., & Emery, P. (2003) · PubMed · Cited by 174
Calabrese, L. H., & Duna, G. F. (1996) · Current Opinion in Rheumatology · doi:10.1097/00002281-199601000-00006 · Cited by 165
Genovese, M. C., Bathon, J. M., Fleischmann, R., Moreland, L. W., Martin, R. W., Whitmore, J. B., Tsuji, W. H., & Leff, J. A. (2005) · PubMed · Cited by 135
Leukocytoclastic vasculitis due to etanercept.
Galaria, N. A., Werth, V. P., & Schumacher, H. R. (2000) · PubMed · Cited by 130
Pulmonary complications of infliximab therapy in patients with rheumatoid arthritis.
Östör, A. J. K., Chilvers, E. R., Somerville, M. F., Lim, A. Y. N., Lane, S. E., Crisp, A. J., & Scott, D. G. I. (2006) · PubMed · Cited by 126
Nurmohamed, M. T., & Dijkmans, B. A. C. (2005) · Drugs · doi:10.2165/00003495-200565050-00006 · Cited by 110
Etanercept and infliximab associated with cutaneous vasculitis
McCain, M. (2002) · British journal of rheumatology · doi:10.1093/rheumatology/41.1.116 · Cited by 99
Merkel, P. A. (2001) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(05)70239-8 · Cited by 98
Differentiating the efficacy of the tumor necrosis factor inhibitors
Haraoui, B. P. (2005) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2005.01.003 · Cited by 95
A Lupus-like Syndrome Associated With Infliximab Therapy
Klapman, J. B., Ene‐Stroescu, D., Becker, M. A., & Hanauer, S. B. (2003) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200305000-00005 · Cited by 82
Pulmonary fibrosis in a patient with rheumatoid arthritis treated with adalimumab
Schoe, A., van der Laan‐Baalbergen, N., Huizinga, T. W. J., Breedveld, F. C., & van Laar, J. M. (2006) · Arthritis Care & Research · doi:10.1002/art.21716 · Cited by 81
Pulmonary sarcoidosis developing during infliximab therapy
O'Shea, F. D., Marras, T. K., & Inman, R. D. (2006) · Arthritis Care & Research · doi:10.1002/art.22351 · Cited by 79
Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis
Kramer, N., Chuzhin, Y., Kaufman, L. D., Ritter, J. M., & Rosenstein, E. D. (2002) · Arthritis Care & Research · doi:10.1002/art.10803 · Cited by 77
Etanercept-induced systemic lupus erythematosus
Swale, V. J., Perrett, C. M., Denton, C. P., Black, C. M., & Rustin, M. H. A. (2003) · Clinical and Experimental Dermatology · doi:10.1046/j.1365-2230.2003.01411.x · Cited by 76
Interstitial pneumonitis associated with infliximab therapy.
Villeneuve, É., St-Pierre, A., & Haraoui, B. P. (2006) · PubMed · Cited by 74
Etanercept‐induced lupus‐like syndrome in a patient with rheumatoid arthritis
Carlson, E., & Rothfield, N. F. (2003) · Arthritis & Rheumatism · doi:10.1002/art.11033 · Cited by 71
Richette, P., Dieudé, P., Damiano, J., Lioté, F., Orcel, P., & Bardin, T. (2004) · PubMed · Cited by 70
Infliximab-induced lupus in Crohn’s disease: a case report
Sarzi‐Puttini, P., Ardizzone, S., Manzionna, G., Atzeni, F., Colombo, E. M., Antivalle, M., Carrabba, M., & Bianchi-Porro, G. (2003) · Digestive and Liver Disease · doi:10.1016/s1590-8658(03)00448-1 · Cited by 66
Severe interstitial pneumonitis associated with infliximab therapy
Chatterjee, S. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410005836 · Cited by 64
Polymyositis associated with infliximab treatment for rheumatoid arthritis
Musial, J. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg388 · Cited by 64
Granulomatous lung disease occurring during etanercept treatment
Phillips, K., & Weinblatt, M. E. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21336 · Cited by 61
Discoid lupus erythematosus-like eruption induced by infliximab
Stratigos, A., Antoniou, C., Stamathioudaki, S., Avgerinou, G., Tsega, A., & Katsambas, A. D. (2004) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2004.01471.x · Cited by 60
Bieber, J. D., & Kavanaugh, A. (2004) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2004.01.003 · Cited by 51
Doulton, T. W. R., Tucker, B., Reardon, J., & Velasco, N. (2004) · Clinical Nephrology · doi:10.5414/cnp62234 · Cited by 50
Musculoskeletal manifestations and autoimmune diseases related to new biologic agents
Haraoui, B. P., & Keystone, E. C. (2005) · Current Opinion in Rheumatology · doi:10.1097/01.bor.0000198007.73320.6e · Cited by 49
Drug-Induced Lupus After Treatment With Infliximab in Rheumatoid Arthritis
Benucci, M., Gobbi, F. L., Fossi, F., Manfredi, M., & Rosso, A. D. (2005) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000152148.55133.ba · Cited by 49
Immunology of Cutaneous Vasculitis Associated with both Etanercept and Infliximab
Srivastava, M., Alexander, F., & Tuthill, R. J. (2005) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2005.01570.x · Cited by 48
Nancey, S., Blanvillain, E., Parmentier, B., Flourié, B., Bayet, C., Bienvenu, J., & Fabien, N. (2005) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000186408.07769.78 · Cited by 46
Hypersensitivity Vasculitis with Leukocytoclastic Vasculitis Secondary to Infliximab
McIlwain, L., Carter, J. D., Bin-Sagheer, S. T., Vasey, F. B., & Nord, J. (2003) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200305000-00010 · Cited by 46
Henoch-Schönlein Purpura After Etanercept Therapy for Psoriasis
Lee, A., Kasama, R. K., Evangelisto, A. M., Elfenbein, B., & Falasca, G. F. (2006) · JCR Journal of Clinical Rheumatology · doi:10.1097/01.rhu.0000239901.34561.5e · Cited by 43
Infliximab-Induced Lupus Erythematosus Tumidus in a Patient With Rheumatoid Arthritis
Schneider, S. W., Ständer, S., Schlüter, B., Luger, T. A., & Bonsmann, G. (2006) · Archives of Dermatology · doi:10.1001/archderm.142.1.115 · Cited by 43
Diffuse Alveolar Hemorrhage After Infliximab Treatment of Crohnʼs Disease
Panagi, S., Palka, W., Korelitz, B. I., Taskin, M., & Lessnau, K. (2004) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200405000-00016 · Cited by 40
van Rijthoven, A. W. A. M., Bijlsma, J. W. J., van Dijk, M. R., Derksen, R. H. W. M., & van Roon, J. A. G. (2006) · Lara D. Veeken · doi:10.1093/rheumatology/kel227 · Cited by 37
Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis
Courtney, P. A., Alderdice, J. M., & Whitehead, E. M. (2003) · Arthritis Care & Research · doi:10.1002/art.11187 · Cited by 35
Etanercept-Induced Systemic Lupus Erythematosus in a Patient with Rheumatoid Arthritis
Kang, M., Lee, Y. H., & Lee, J. (2006) · Journal of Korean Medical Science · doi:10.3346/jkms.2006.21.5.946 · Cited by 35
Christopher‐Stine, L., & Wigley, F. M. (2003) · PubMed · Cited by 35
Giant cell arteritis in a patient taking etanercept and methotrexate.
Seton, M. (2004) · PubMed · Cited by 33
Roux, C. H., Brocq, O., Breuil, V., & Euller‐Ziegler, L. (2004) · Joint Bone Spine · doi:10.1016/j.jbspin.2004.05.008 · Cited by 28
Interstitial pneumonitis after infliximab therapy for Crohnʼs disease
Weatherhead, M., Masson, S., Bourke, S., Gunn, M., & Burns, G. (2006) · Inflammatory Bowel Diseases · doi:10.1097/01.mib.0000219811.54115.aa · Cited by 27
Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab
Pérez-García, C., Maymó, J., Pérez, M. P. L., Almirall, M., & Abelló, J. C. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/kei220 · Cited by 23
Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis
Pallotta, P., Cianchini, G., Ruffelli, M., & Puddu, P. (2005) · Lara D. Veeken · doi:10.1093/rheumatology/kei227 · Cited by 22
Martínez-Taboada, V., Val‐Bernal, J. F., Lc, P., Fernández-Llanio, N., Esteban, J. M., Blanco, R., Alonso-Bartolomé, P., González‐Vela, C., & Rodrı́guez-Valverde, V. (2006) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740600557249 · Cited by 18
Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis
Anandacoomarasamy, A., Kannangara, S., & Barnsley, L. (2005) · Internal Medicine Journal · doi:10.1111/j.1445-5994.2005.00899.x · Cited by 13
Novak, S., & Cikes, N. (2004) · PubMed · Cited by 9
Komuro (2001) · doi:10.1002/1529-0131(200112)44:12
Shigeyama (2000) · doi:10.1002/1529-0131(200011)43:11
Cited by
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Regulation of tumour necrosis factor signalling: live or let die
Brenner, D., Blaser, H., & Mak, T. W. (2015) · Nature Reviews Immunology · doi:10.1038/nri3834 · Cited by 998
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010
Furst, D. E., Keystone, E. C., Braun, J., Breedveld, F. C., Burmester, G. R., De Benedetti, F., Dörner, T., Emery, P., Fleischmann, R., Gibofsky, A., et al. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.146852 · Cited by 687
Rheumatoid Arthritis–Interstitial Lung Disease–associated Mortality
Olson, A. L., Swigris, J. J., Sprunger, D. B., Fischer, A., Fernandez-Perez, E. R., Solomon, J., Murphy, J., Cohen, M., Raghu, G., & Brown, K. K. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201004-0622oc · Cited by 544
British Association of Dermatologists’ guidelines for biologic interventions for psoriasis 2009
Smith, C. H., Anstey, A. V., Barker, J. N. W. N., Burden, A. D., Chalmers, R. J. G., Chandler, D. A., Finlay, A. Y., Griffiths, C. E. M., Jackson, K., McHugh, N. J., et al. (2009) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2009.09505.x · Cited by 464
Metadata
- Authors
- Ramos-Casals, M., Brito-Zerón, P., Muñoz, S., Soria, N., Galiana, D., Bertolaccini, L., Cuadrado, M.-J., & Khamashta, M. A.
- Venue
- Medicine
- Published
- 2007-07
- Volume
- 86
- Issue
- 4
- Pages
- 242-251
- ISSN
- 0025-7974 (ISSN-L)
- OpenAlex
- W2029993898
- Cited by
- 733
- References
- 65
- FWCI
- 35.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.